Amy Crouch

Amy is a life sciences expert with extensive experience of high-profile patent litigation involving some of the highest-revenue pharmaceuticals on the market. Her experience spans the full spectrum of life sciences patent disputes before the UK courts, ranging from small molecule and biologic disputes to the UK’s first gene therapy patent case to go to trial. 

She also has a wealth of experience coordinating multi-jurisdictional litigation across Europe and with the US, as well as aligning litigation strategy with opposition proceedings before the EPO. Amy also has experience of acting for clients on UPC litigation and of advising clients on the ever-increasing importance of UPC litigation strategy and its integration with UK and European national litigation strategy.

Areas of Expertise

• UK Patent Litigation 
• Pan-European Patent Litigation 
• UPC Patent Litigation 
• Freedom to Operate Advice 
• Advisory 

Qualifications & Background

Amy has an MSci in Biochemistry (First Class Honours) from Imperial College London. She went on to study law, qualified as a solicitor in 2011 and obtained the Postgraduate Diploma in IP Law and Practice from the University of Oxford. 

Amy is passionate about diversity and inclusion and is the co-chair of the London chapter of ChIPs, a prominent organisation that promotes women in tech, law and policy. She is also on the organising committee for the annual ChIPs European Summit.

She is a lecturer on patent validity at the IP Law Summer School at the University of Cambridge and was previously an organiser of the IP module of the University of Cambridge’s MPhil in Bioscience Enterprise. 

Amy joined the firm in October 2025, having previously worked in another leading UK patent litigation team for 15 years. 

Key Cases:

• Pfizer vs uniQure/CSL Behring (Haemophilia B gene therapy)
• Samsung Bioepis vs Alexion (eculizumab) 
• Samsung Bioepis vs Novartis (ranibizumab) 
• UCB vs Genentech/Novartis (anti-IL-17 antibodies) 
• Teva vs Bayer (sorafenib) 
• Samsung Bioepis vs Gedeon Richter (adalimumab) 
• Samsung Bioepis vs Fresenius (adalimumab)
• Samsung Bioepis vs AbbVie (adalimumab) 
• Merck vs Ono/BMS (anti-PD1 antibodies) 
• Eli Lilly vs Janssen (anti-ABeta antibodies) 

Recommendations and Feedback

• IAM 1000 (2024):  “Crouch’s background in biochemistry serves her well, and she understands the technical details of the patents on trial as well as the complexities of the legal questions raised”
• Manging IP Rising Star (2019-2025)
• Legal 500 Life Sciences & Healthcare (2023):  “excellent practitioner”; previously praised for “deep technical understanding”
• Who’s Who Legal Life Sciences - Leading Individual for Patent Litigation in (2021-2025): “a star who has experience in managing and coordinating extensive blockbuster pan-European patent litigation”; “a superstar senior associate who knows everything there is to know about biosimilar litigation”
• Who’s Who Legal IP - Patents - Patent Litigation Leading Individual (2022-2025: “Amy Crouch is lauded as “an absolute star in patent work” who possesses “impressive technical skills”)
• Rising star for Life Sciences in the United Kingdom by Expert Guides (2022)

Memberships and Affiliations

AIPPI
ChIPs